BioPorto A/S (CPSE: BIOPOR)
Health Care · Biotechnology · DK
Dkr1.20
-5.88% today · -0.9% 1Y
BioPorto A/S (CPSE: BIOPOR) operates in the Biotechnology industry within the Health Care sector. The company is valued at $98.60M and employs 46 people.
Over the last twelve months the share price has lost 0.9%, trading between 0.84 and 1.49.
Tweenvest scores BioPorto A/S across four factors: quality 34/100, value 49/100, growth 65/100. Its strongest factor is growth.
BIOPOR price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $98.60M
- Revenue (TTM)
- $6.33M
- P/E
- —
- EPS
- -0.15
- Dividend yield
- —
- Beta (5Y)
- 1.38
- 52-week high
- Dkr1.49
- 52-week low
- Dkr0.84
- Avg volume (3M)
- —
- Shares outstanding
- 495.11M
- Employees
- 46
- Next earnings
- —
About BioPorto A/S
BioPorto A/S is a Danish in-vitro diagnostics specialist, supplying biomarker tests, research tools, and antibodies to medical professionals and scientists worldwide, with operations across Europe, North America, and Asia. Among its offerings is the neutrophil gelatinase-associated lipocalin (NGAL) test, a precise quantitative particle-enhanced turbidimetric immunoassay designed for use on automated chemistry analyzers. The company further provides monoclonal antibodies essential for scientific, pharmaceutical, and clinical investigations. Additionally, BioPorto produces enzyme-linked immunosorbent assay (ELISA) kits and a versatile rapid assay device tailored for custom lateral flow assay development. Established in 1917, the company is headquartered in Hellerup, Denmark.
- ISIN
- DK0011048619
- Founded
- 1917
- Listed since
- Jan 13, 2000
- Exchange
- OMX Nordic Exchange Copenhagen
- Currency
- DKK
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $443.84 | +1.03% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $65.85B | €864.20 | -4.19% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $138.89 | -4.26% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.